On Monday, H.C. Wainwright adjusted its price target for Purple Biotech Ltd. (NASDAQ: PPBT) to $8.00 from the previous $10.00 while maintaining a Buy rating on the stock. This change follows Purple Biotech's recent announcement on August 16 regarding its second-quarter 2024 earnings and a corporate update.
Purple Biotech reported on its ongoing CM24 Phase 2 study for second-line pancreatic cancer (PDAC) treatment. The study consists of two randomized cohorts, each evaluating different chemotherapy regimens in combination with CM24 and nivolumab. Positive interim data from the Nal-IRI cohort were presented at the American Society of Clinical Oncology (ASCO) meeting in June 2024.
However, the company encountered issues with the gem/nab-paclitaxel cohort, specifically informative censoring in the control arm that led to an imbalance between the active and control arms. This issue rendered the cohort unsuitable for analysis, which will affect the final topline data expected in the fourth quarter of 2024.
Despite the setback with the gem/nab-paclitaxel cohort, the company clarified that this does not impact the previously reported interim results from the Nal-IRI cohort. Purple Biotech is currently exploring partnership opportunities for a Phase 3 trial but is also considering proceeding independently if it can secure the necessary funding. The firm reiterated its Buy rating for Purple Biotech but reduced the price target due to the recent developments.
Purple Biotech has made significant strides in its clinical developments and market standing. The company recently received a 180-day extension from Nasdaq to meet the stock market's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market until January 21, 2025.
On the clinical front, Purple Biotech is progressing with its oncology therapies. The company's pipeline includes NT219, CM24, and IM1240, with NT219 undergoing a concluded Phase 1 study and a planned Phase 2 study for treating recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is in a Phase 2 study combined with nivolumab and chemotherapy for pancreatic ductal adenocarcinoma (PDAC), under a clinical collaboration with Bristol Myers (NYSE:BMY) Squibb.
Analysts from H.C. Wainwright and Jones Trading have maintained a Buy rating on Purple Biotech, despite Jones Trading lowering its price target due to concerns over future data readouts. The firm adjusted the probability of success for CM24 from 35% to 20%.
Recent findings from a Phase 2 study indicate that the company's CM24, in combination with nivolumab and standard chemotherapy, may improve survival outcomes for PDAC patients. The CM24 treatment arm saw a 26% reduction in the risk of death and a 28% reduction in the risk of disease progression or death.
InvestingPro Insights
As Purple Biotech Ltd. (NASDAQ: PPBT) navigates through its clinical trials and corporate updates, investors may find it useful to consider recent financial data and analysis provided by InvestingPro. A crucial InvestingPro Tip highlights that Purple Biotech holds more cash than debt on its balance sheet, which could provide some financial flexibility as the company explores partnership opportunities or seeks funding for further trials. However, it is also noted that the company is quickly burning through cash, a factor that investors should monitor closely.
From a valuation perspective, Purple Biotech's market capitalization stands at $12.51 million, reflecting the company's current scale in the biotech landscape. Additionally, the stock is trading near its 52-week low, with a price of $0.37 at the previous close, which might indicate a potential entry point for investors believing in the company's long-term prospects despite recent setbacks. The company's price/book ratio as of Q2 2024 is 0.43, which could suggest that the stock is undervalued relative to its assets, though this must be weighed against its negative gross profit margins and significant operating losses.
For investors seeking a comprehensive analysis, there are additional InvestingPro Tips available, providing deeper insights into Purple Biotech's financial health and market position. These tips can be accessed through the dedicated InvestingPro platform for Purple Biotech at https://www.investing.com/pro/PPBT.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.